Sandoz Targets $650 Billion Opportunity With Biosimilars Unit
Swiss generic drugmaker Sandoz Group AG has created a global biosimilars unit to capitalize on drugs worth $650 billion losing patent protection over the next decade.
By Isabel Demetz, Paula Doenecke · Bloomberg
Swiss generic drugmaker Sandoz Group AG has created a global biosimilars unit to capitalize on drugs worth $650 billion losing patent protection over the next decade.